Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Aug 31, 2023
AI Success Story: Trader Robot Boosts $NVDA by +8.37% Last Week

AI Success Story: Trader Robot Boosts $NVDA by +8.37% Last Week

One notable example is the "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)" bot, which has demonstrated its prowess as more than just a trading tool – it's a bot factory generating remarkable gains. Over the previous week, this AI trading bot managed to achieve a remarkable +8.37% gain by actively trading NVDA, a clear testament to the potential of combining technical and fundamental analysis with automated trading strategies.

NVDA's RSI Indicator Signals a Shift in Momentum

One crucial technical indicator that the AI bot leveraged is the Relative Strength Index (RSI), a momentum oscillator that measures the speed and change of price movements. On August 14, 2023, NVDA's RSI Indicator moved out of oversold territory, suggesting a potential shift from a downward trend to an upward trajectory. This is a pivotal signal for traders, indicating an opportunity to consider buying the stock or call options.

To provide context, the AI bot studied 20 similar instances when NVDA's RSI Indicator exited oversold territory. Remarkably, in 19 out of these 20 cases, the stock exhibited upward movement. This impressive historical performance establishes the odds of a price surge at an encouraging 90%, reinforcing the reliability of the RSI Indicator as a predictive tool for traders.

Earnings Report Surpasses Estimates

Beyond the technical signals, fundamental analysis played a significant role in the bot's successful trading strategy. The latest earnings report, released on August 23, revealed earnings per share (EPS) of $2.70, surpassing the estimated value of $2.07. With 27.66 million shares outstanding, the current market capitalization of NVDA stands at an impressive $1.20 trillion.

This earnings outperformance not only reflects the company's strong financial health but also underscores the effectiveness of the AI bot's approach in identifying lucrative trading opportunities. The ability to factor in fundamental data alongside technical indicators enhances the bot's capacity to make well-informed trading decisions.

Summary

The amalgamation of advanced AI algorithms, technical analysis, and fundamental insights has propelled AI trading bots into the forefront of modern trading strategies. The remarkable +8.37% gain achieved by the "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)" bot while trading NVDA over the past week serves as a tangible testament to their potential. With the RSI Indicator hinting at a shift in momentum and earnings surpassing expectations, these AI trading bots have showcased their capacity to navigate the complex landscape of the stock market with impressive precision.

Related Ticker: NVDA

Contributor

Dem Sem's AvatarDem Sem|Expert

Aroon Indicator for NVDA shows an upward move is likely

NVDA's Aroon Indicator triggered a bullish signal on July 31, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 344 similar instances where the Aroon Indicator showed a similar pattern. In of the 344 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on NVDA as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NVDA just turned positive on August 04, 2026. Looking at past instances where NVDA's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

NVDA moved above its 50-day moving average on August 03, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVDA advanced for three days, in of 355 cases, the price rose further within the following month. The odds of a continued upward trend are .

NVDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVDA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. NVDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NVDA's P/B Ratio (27.778) is very high in comparison to the industry average of (8.614). P/E Ratio (34.297) is within average values for comparable stocks, (166.940). Projected Growth (PEG Ratio) (0.617) is also within normal values, averaging (1.982). NVDA has a moderately low Dividend Yield (0.001) as compared to the industry average of (0.014). P/S Ratio (21.598) is also within normal values, averaging (48.971).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Broadcom Inc. (NASDAQ:AVGO), Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM), Micron Technology (NASDAQ:MU), Advanced Micro Devices (NASDAQ:AMD), Intel Corp (NASDAQ:INTC), Texas Instruments (NASDAQ:TXN), Marvell Technology (NASDAQ:MRVL), Analog Devices (NASDAQ:ADI), QUALCOMM (NASDAQ:QCOM).

Industry description

The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.

Market Cap

The average market capitalization across the Semiconductors Industry is 191.15B. The market cap for tickers in the group ranges from 13.43K to 5.42T. NVDA holds the highest valuation in this group at 5.42T. The lowest valued company is CYBL at 13.43K.

High and low price notable news

The average weekly price growth across all stocks in the Semiconductors Industry was 11%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 48%. WOLF experienced the highest price growth at 39%, while LASR experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Semiconductors Industry was -17%. For the same stocks of the Industry, the average monthly volume growth was -16% and the average quarterly volume growth was -62%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 53
Price Growth Rating: 46
SMR Rating: 75
Profit Risk Rating: 72
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
NVDA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of computer graphics processors, chipsets, and related multimedia software

Industry Semiconductors

Profile
Details
Industry
Semiconductors
Address
2788 San Tomas Expressway
Phone
+1 408 486-2000
Employees
42000
Web
https://www.nvidia.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.